AA
IOBT

Ancora Advisors’s IO Biotech IOBT Stock Holding History

Ancora Advisors’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-908
Closed -$1.28K – 1797
2023
Q3 		$1.28K Hold
908
– – ﹤0.01% 1539
2023
Q2 		$1.77K Hold
908
– – ﹤0.01% 1495
2023
Q1 		$1.7K Hold
908
– – ﹤0.01% 1549
2022
Q4 		$2K Hold
908
– – ﹤0.01% 1593
2022
Q3 		$2K Buy
+908
New +$3.37K ﹤0.01% 1796

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Ancora Advisors's IOBT Position: Q4 2023 in Review

Ancora Advisors sold out of IO Biotech (IOBT) in Q4 2023, closing a stake of 908 shares — an estimated $1.28K sold.

Ancora Advisors first reported a position in IOBT in Q3 2022 and held it in 5 quarters. The position peaked at $2K in Q4 2022. 18 funds tracked by Wall St. Rank hold IOBT as of Q4 2023.

  • Ancora Advisors reported no remaining IO Biotech position as of Q4 2023 after selling out during the quarter.
  • Ancora Advisors sold 908 IO Biotech shares in Q4 2023, an estimated $1.28K.
  • Ancora Advisors first reported a position in IO Biotech in Q3 2022 and held it in 5 quarters.
  • Ancora Advisors's IO Biotech position peaked at $2K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held IO Biotech as of Q4 2023.

Based on Ancora Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.